265. Lipodystrophy Clinical trials / Disease details

Clinical trials : 112 / Drugs : 155 - (DrugBank : 55) / Drug target genes : 25 - Drug target pathways : 97

13 trials found

diseases per page:

Showing 1 to 10 of 13 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05164341 (ClinicalTrials.gov)	December 17, 2021	11/11/2021	Study to Evaluate the Safety and Efficacy of Daily Subcutaneous MetreleptinTreatment in Subjects Wit ...	A 12-Month Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the S ...	Partial Lipodystrophy	Drug: metreleptin;Drug: Placebo	Amryt Pharma	NULL	Recruiting	12 Years	N/A	All	65	Phase 3	United States;Canada
2	NCT04026178 (ClinicalTrials.gov)	November 14, 2018	30/10/2018	Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy	A 36-Month, Multicenter, Open Label Phase 4 Study to Evaluate the Immunogenicity of Daily SC Metrele ...	Generalized Lipodystrophy	Drug: Metreleptin	Aegerion Pharmaceuticals, Inc.	NULL	Recruiting	1 Year	N/A	All	10	Phase 4	United States
3	EUCTR2017-003014-22-AT (EUCTR)	25/06/2018	29/05/2018	Leptin in hepatic lipid metabolism in humans	The role of leptin in regulating hepatic lipid metabolism in humans - Leptin and hepatic lipid metab ...	lipodystrophy patients, patients after liver transplantation and healthy controls;Therapeutic area: ...	Trade Name: Myalept Product Name: Myalept INN or Proposed INN: metrelpetin Other descriptive name: METR ...	Medical University of Vienna	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	43	Phase 2	Austria
4	NCT02654977 (ClinicalTrials.gov)	September 29, 2015	20/1/2015	CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptinin Various Forms of ...	CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Recombinant Human Leptin (METR ...	Familial Partial Lipodystrophy;Nonalcoholic Steatohepatitis;NAFLD	Drug: Metreleptin	University of Michigan	NULL	Completed	5 Years	N/A	All	11	Phase 2	United States
5	NCT02262806 (ClinicalTrials.gov)	October 14, 2014	9/10/2014	Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy	Compassionate Use of Metreleptin in Previously-Treated Patients With Partial Lipodystrophy	Diabetes;Lipodystrophy;Hyperlipidemia	Drug: Metreleptin	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	NULL	Active, not recruiting	6 Months	N/A	All	30	Phase 2	United States
6	NCT02262832 (ClinicalTrials.gov)	October 9, 2014	10/10/2014	Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy	Compassionate Use of Metreleptin in Previously-Treated Patients With Generalized Lipodystrophy	Lipodystrophy;Diabetes;Hyperlipidemia	Drug: Metreleptin	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	NULL	Recruiting	6 Months	N/A	All	30	Phase 3	United States
7	NCT02404896 (ClinicalTrials.gov)	September 16, 2014	20/1/2015	Expanded Access Metreleptin Study	Expanded-Access for the Use of Metreleptinin Patients With Partial Lipodystrophy Associated With Dia ...	Familial Partial Lipodystrophy	Drug: Metreleptin	University of Michigan	NULL	Available	18 Years	N/A	All			United States
8	NCT01778556 (ClinicalTrials.gov)	January 26, 2013	26/1/2013	Short-term Effects of Leptin in People With Lipodystrophy	Short Term Effects of Leptin Withdrawal or Initiation in Lipodystrophy Independent of Energy Intake	Lipodystrophy	Biological: Metreleptin	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	NULL	Completed	14 Years	70 Years	All	25	Phase 2	United States
9	NCT01679197 (ClinicalTrials.gov)	October 8, 2012	31/8/2012	Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoho ...	Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoho ...	Fatty Liver Disease, Nonalcoholic;Nonalcoholic Steatohepatitis;Lipodystrophy	Drug: Metreleptin	University of Michigan	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	5 Years	N/A	All	23	Phase 2	United States
10	NCT00677313 (ClinicalTrials.gov)	November 2008	12/5/2008	An Open-Label Treatment Protocol to Provide Metreleptinfor the Treatment of Diabetes Mellitus and/or ...	An Open-Label Treatment Protocol to Provide Metreleptinfor the Treatment of Diabetes Mellitus and/or ...	Lipodystrophy	Drug: metreleptin	Bristol-Myers Squibb	NULL	Active, not recruiting	5 Years	N/A	Both	41	N/A	United States

First Previous1 2Next Last